Results 271 to 280 of about 106,446 (312)
Some of the next articles are maybe not open access.
Angiotensin receptor blockers in diabetic nephropathy
Current Diabetes Reports, 2001Where shall we place angiotensin receptor blockers in the scheme of the prevention of diabetic nephropathy? Only the results of a large, randomized double-blind trial with a comparable and appropriate alternative would prove therapeutic efficacy. The results of several trials with angiotensin-converting enzyme (ACE) inhibitors have proven them to be ...
D A, Price, N K, Hollenberg
openaire +2 more sources
Fimasartan: A New Angiotensin Receptor Blocker
Drugs, 2016Fimasartan is the ninth, and most recent, angiotensin II receptor antagonist approved as an antihypertensive agent. Fimasartan, a pyrimidin-4(3H)-one derivative of losartan with the imidazole ring replaced, which enables higher potency and longer duration than losartan. Fecal elimination and biliary excretion are the predominant elimination pathways of
Hae-Young, Lee, Byung-Hee, Oh
openaire +2 more sources
2011
Angiotensin receptor blockers (ARBs) were developed to providean alternative approach to interrupting the renin–angiotensin system(RAS), which was pharmacologically distinct from that ofangiotensin converting enzyme (ACE) inhibitors. By selectivelyblocking the angiotensin II type 1 (AT1) receptor, ARBs werethought to offer the potential for more ...
openaire +1 more source
Angiotensin receptor blockers (ARBs) were developed to providean alternative approach to interrupting the renin–angiotensin system(RAS), which was pharmacologically distinct from that ofangiotensin converting enzyme (ACE) inhibitors. By selectivelyblocking the angiotensin II type 1 (AT1) receptor, ARBs werethought to offer the potential for more ...
openaire +1 more source
Angiotensin receptor blockers following acute stroke
Expert Review of Cardiovascular Therapy, 2011Elevated blood pressure during the acute stroke period is associated with poor neurologic outcomes; however, treating blood pressure in this setting remains controversial. Interest in modulating the renin-angiotensin system in this setting has gained momentum because of neurohormonal properties, which may provide benefits beyond blood pressure control.
Denise H, Rhoney, Lynette R, Moser
openaire +2 more sources
Angiotensin II Receptor Blockers
2001The angiotensin II (Ang II) receptor antagonists are the most selective blockers of the renin-angiotensin system (RAS) currently available. The efficacy of these drugs is similar to that of the other major antihypertensive drug classes, but they appear to exhibit fewer side effects. Angiotensin receptor blockers (ARBs) selectively block the angiotensin
openaire +1 more source
Vascular benefits of angiotensin receptor blockers
Expert Opinion on Investigational Drugs, 2007There is convincing evidence that angiotensin II, through activation of the angiotensin II type 1 (AT1) receptor, is involved in the atherosclerotic process. Similarly, angiotensin receptor blockers decrease vascular inflammation, hypertrophy and thrombosis, which are the key components of the progression of atherosclerosis.
openaire +2 more sources
Angiotensin II receptor blockers
Coronary Artery Disease, 1999H, Thai, T, Raya
openaire +2 more sources
Angiotensin Receptor Blockers and Parkinson Disease
The American Journal of Medicine, 2023Noriaki Kou +4 more
openaire +2 more sources